skip to content
Pharmacogenetic studies in multiple myeloma Preview this item
ClosePreview this item
Checking...

Pharmacogenetic studies in multiple myeloma

Author: Sophie Corthals
Publisher: Erasmus University Rotterdam 2011-05-11
Edition/Format: Book Book : English
Summary:
textabstractMultiple myeloma (MM) is a malignant plasma cell disorder that accounts for approximately 10%of all hematologic cancers.1-2 MM is characterized by clonal proliferation of malignant plasmacells in the bone marrow, which secrete a homogeneous immunoglobulin product known asmonoclonal (M) protein or paraprotein. Typical features of MM include osteolytic bone lesions,renal disease, anemia, hypercalcemia and  Read more...
Rating:

(not yet rated) 0 with reviews - Be the first.

Find a copy online

Links to this item

Find a copy in the library

We were unable to get information about libraries that hold this item.

Details

Document Type: Book
All Authors / Contributors: Sophie Corthals
ISBN: 978-94-6169-034-0
Language Note: English
Unique Identifier: 6893683517
Awards:

Abstract:

textabstractMultiple myeloma (MM) is a malignant plasma cell disorder that accounts for approximately 10%of all hematologic cancers.1-2 MM is characterized by clonal proliferation of malignant plasmacells in the bone marrow, which secrete a homogeneous immunoglobulin product known asmonoclonal (M) protein or paraprotein. Typical features of MM include osteolytic bone lesions,renal disease, anemia, hypercalcemia and immunodeficiency.3The pathological development of MM is a multistep process and starts with the emergence ofan asymptomatic premalignant stage of clonal plasma cell proliferation known as “monoclonalgammopathy of undetermined significance” (MGUS), occurring in about 3% of individualsabove the age of 50. MGUS cells secrete monoclonal immunoglobulin (Ig) which may progressto smouldering MM and ultimately to symptomatic intramedullary and extramedullary multiplemyeloma, or plasma cell leukemia; expressing the same Ig. Smouldering MM has a stable intramedullarytumor cell content of >10%, but no osteolytic lesions or other complications ofmalignant MM. Patients with MGUS have a risk to progress to myeloma or a related malignancyat a rate of 1% a year.4-5 The prevalence of both MGUS and MM increases markedly with age,and is slightly more common in men than in women. The incidence is about two-fold higherin African Americans than in Caucasians. The median length of survival after diagnosis is approximately3-5 years.

Reviews

User-contributed reviews
Retrieving GoodReads reviews...
Retrieving DOGObooks reviews...

Tags

Be the first.
Confirm this request

You may have already requested this item. Please select Ok if you would like to proceed with this request anyway.

Linked Data


\n\n

Primary Entity<\/h3>\n
<http:\/\/www.worldcat.org\/oclc\/6893683517<\/a>> # Pharmacogenetic studies in multiple myeloma<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Book<\/a>, schema:CreativeWork<\/a> ;\u00A0\u00A0\u00A0\nlibrary:oclcnum<\/a> \"6893683517<\/span>\" ;\u00A0\u00A0\u00A0\nrdfs:comment<\/a> \"949 $l doctoralthesis<\/span>\" ;\u00A0\u00A0\u00A0\nschema:about<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/3985289891#Thing\/hematology<\/a>> ; # hematology<\/span>\n\u00A0\u00A0\u00A0\nschema:about<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/3985289891#Thing\/multiple_myeloma<\/a>> ; # multiple myeloma<\/span>\n\u00A0\u00A0\u00A0\nschema:about<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/3985289891#Thing\/blood_cells<\/a>> ; # blood cells<\/span>\n\u00A0\u00A0\u00A0\nschema:about<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/3985289891#Thing\/plasma_cell_disorder<\/a>> ; # plasma cell disorder<\/span>\n\u00A0\u00A0\u00A0\nschema:about<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/3985289891#Thing\/cancer<\/a>> ; # cancer<\/span>\n\u00A0\u00A0\u00A0\nschema:creator<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/3985289891#Person\/corthals_sophie<\/a>> ; # Sophie Corthals<\/span>\n\u00A0\u00A0\u00A0\nschema:datePublished<\/a> \"2011\/05\/11<\/span>\" ;\u00A0\u00A0\u00A0\nschema:description<\/a> \"textabstractMultiple myeloma (MM) is a malignant plasma cell disorder that accounts for approximately 10%of all hematologic cancers.1-2 MM is characterized by clonal proliferation of malignant plasmacells in the bone marrow, which secrete a homogeneous immunoglobulin product known asmonoclonal (M) protein or paraprotein. Typical features of MM include osteolytic bone lesions,renal disease, anemia, hypercalcemia and immunodeficiency.3The pathological development of MM is a multistep process and starts with the emergence ofan asymptomatic premalignant stage of clonal plasma cell proliferation known as \u201Cmonoclonalgammopathy of undetermined significance\u201D (MGUS), occurring in about 3% of individualsabove the age of 50. MGUS cells secrete monoclonal immunoglobulin (Ig) which may progressto smouldering MM and ultimately to symptomatic intramedullary and extramedullary multiplemyeloma, or plasma cell leukemia; expressing the same Ig. Smouldering MM has a stable intramedullarytumor cell content of >10%, but no osteolytic lesions or other complications ofmalignant MM. Patients with MGUS have a risk to progress to myeloma or a related malignancyat a rate of 1% a year.4-5 The prevalence of both MGUS and MM increases markedly with age,and is slightly more common in men than in women. The incidence is about two-fold higherin African Americans than in Caucasians. The median length of survival after diagnosis is approximately3-5 years.<\/span>\" ;\u00A0\u00A0\u00A0\nschema:exampleOfWork<\/a> <http:\/\/worldcat.org\/entity\/work\/id\/3985289891<\/a>> ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"Pharmacogenetic studies in multiple myeloma<\/span>\" ;\u00A0\u00A0\u00A0\nschema:productID<\/a> \"6893683517<\/span>\" ;\u00A0\u00A0\u00A0\nschema:publication<\/a> <http:\/\/www.worldcat.org\/title\/-\/oclc\/#PublicationEvent\/erasmus_university_rotterdam2011_05_11<\/a>> ;\u00A0\u00A0\u00A0\nschema:publisher<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/3985289891#Agent\/erasmus_university_rotterdam<\/a>> ; # Erasmus University Rotterdam<\/span>\n\u00A0\u00A0\u00A0\nschema:url<\/a> <http:\/\/hdl.handle.net\/1765\/23439<\/a>> ;\u00A0\u00A0\u00A0\nschema:workExample<\/a> <http:\/\/worldcat.org\/isbn\/978-94-6169-034-0<\/a>> ;\u00A0\u00A0\u00A0\nwdrs:describedby<\/a> <http:\/\/www.worldcat.org\/title\/-\/oclc\/6893683517<\/a>> ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n\n

Related Entities<\/h3>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/3985289891#Agent\/erasmus_university_rotterdam<\/a>> # Erasmus University Rotterdam<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nbgn:Agent<\/a> ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"Erasmus University Rotterdam<\/span>\" ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/3985289891#Person\/corthals_sophie<\/a>> # Sophie Corthals<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Person<\/a> ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"Sophie Corthals<\/span>\" ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/3985289891#Thing\/blood_cells<\/a>> # blood cells<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Thing<\/a> ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"blood cells<\/span>\" ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/3985289891#Thing\/cancer<\/a>> # cancer<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Thing<\/a> ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"cancer<\/span>\" ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/3985289891#Thing\/hematology<\/a>> # hematology<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Thing<\/a> ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"hematology<\/span>\" ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/3985289891#Thing\/multiple_myeloma<\/a>> # multiple myeloma<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Thing<\/a> ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"multiple myeloma<\/span>\" ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/3985289891#Thing\/plasma_cell_disorder<\/a>> # plasma cell disorder<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Thing<\/a> ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"plasma cell disorder<\/span>\" ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/hdl.handle.net\/1765\/23439<\/a>>\u00A0\u00A0\u00A0\nrdfs:comment<\/a> \"NARCIS<\/span>\" ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/worldcat.org\/isbn\/978-94-6169-034-0<\/a>>\u00A0\u00A0\u00A0\u00A0a \nschema:ProductModel<\/a> ;\u00A0\u00A0\u00A0\nschema:isbn<\/a> \"978-94-6169-034-0<\/span>\" ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/www.worldcat.org\/title\/-\/oclc\/#PublicationEvent\/erasmus_university_rotterdam2011_05_11<\/a>>\u00A0\u00A0\u00A0\u00A0a \nschema:PublicationEvent<\/a> ;\u00A0\u00A0\u00A0\nschema:organizer<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/3985289891#Agent\/erasmus_university_rotterdam<\/a>> ; # Erasmus University Rotterdam<\/span>\n\u00A0\u00A0\u00A0\nschema:startDate<\/a> \"2011-05-11<\/span>\" ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n